Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | TSHR | P16473 | 6/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8601774 | 0.89 | TSHR (0.51) | MAPTTSHRHSD17B10NR3C1PGR | |
| SCHEMBL1492448 | 0.85 | ALDH1A1 (0.55) | MAPTTSHRHSD17B10CYP3A4HPGD | |
| SCHEMBL13344094 | 0.83 | MAPT (0.53) | MAPTTSHRHSD17B10NR3C1PGR | |
| SCHEMBL18138464 | 0.83 | MAPT (0.53) | MAPTTSHRHSD17B10NR3C1PGR | |
| SCHEMBL31747006 | 0.81 | TSHR (0.54) | MAPTTSHRHSD17B10NR3C1PGR | |
| SCHEMBL713941 | 0.81 | TSHR (0.54) | MAPTTSHRHSD17B10NR3C1PGR | |
| SCHEMBL7988274 | 0.81 | MAPT (0.51) | MAPTTSHRHSD17B10NR3C1PGR | |
| SCHEMBL508871 | 0.81 | MAPT (0.51) | MAPTTSHRHSD17B10NR3C1PGR | |
| SCHEMBL27926845 | 0.81 | MAPT (0.51) | MAPTTSHRHSD17B10NR3C1PGR | |
| SCHEMBL10662837 | 0.81 | MAPT (0.51) | MAPTTSHRHSD17B10NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606564-B2 | Adenosine receptor antagonist compounds | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2026-04-21 | — | — | US | disclosed |
| US-20260035361-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | SHANGHAI DEGRON BIOMEDICAL TECH CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-4626880-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | Shanghai Degron Biomedical Technology Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| CN-116425756-B | Adenosine receptor antagonist compounds and uses thereof | 日东制药株式会社 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024242530-A1 | COMPOUND FOR NEUROPROTECTION, OR TREATING DISEASES RELATED TO ALPHA-SYNUCLEIN AND/OR NEURO-INFLAMMATION | YUNOVIA CO., LTD. (KR) | 2024-11-28 | — | — | WO | disclosed |
| CN-114829363-B | Adenosine receptor antagonist compounds | 日东制药株式会社 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024114639-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | SHANGHAI DEGRON BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| US-20240041888-A1 | PREVENTION AND/OR TREATMENT OF CNS DISORDERS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-08 | — | — | US | disclosed |
| US-11806350-B2 | Prevention and/or treatment of CNS disorders | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-11806350-B2 | Prevention and/or treatment of CNS disorders | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-6197965-B1 | POLYARYLALKYLAMINO-SUBSTITUED PYRIDINE DERIVATIVES; DRUGS, MEDICINE, DIAGNOSTICS | ISIS PHARMACEUTICALS, INC. | 2001-03-06 | — | — | US | disclosed |
| EP-0817787-A4 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-1998010286-A1 | METHODS FOR PROCESSING CHEMICAL COMPOUNDS HAVING REACTIVE FUNCTIONAL GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1998-03-12 | — | — | WO | disclosed |
| EP-0817787-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996030377-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0369627-B1 | Pyrimidinedione derivative compounds, method of producing the same and antiarrythmic agents containing the same | MITSUI TOATSU CHEMICALS (JP) | 1994-12-21 | — | — | EP | disclosed |
| US-5008267-A | Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-04-16 | — | — | US | disclosed |
| EP-0369627-A2 | Pyrimidinedione derivative compounds, method of producing the same and antiarrythmic agents containing the same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-05-23 | — | — | EP | disclosed |
| EP-0000718-B1 | QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS AND THEIR PREPARATION | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-03-24 | — | — | EP | disclosed |
| EP-0000718-A2 | Quinazoline derivatives, process for their preparation, pharmaceutical preparations and their preparation | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041888-A1 | PREVENTION AND/OR TREATMENT OF CNS DISORDERS | ADORA2A, ADORA1, ADORA2B | MAPT 615/4885TSHR 620/4885HSD17B10 4713/4885 |
| US-12606564-B2 | Adenosine receptor antagonist compounds | ADORA2A, ADORA1, ADORA2B | MAPT 3225/4885TSHR 136/4885HSD17B10 3252/4885 |
| US-11806350-B2 | Prevention and/or treatment of CNS disorders | ADORA2A, ADORA1, ADORA2B | MAPT 615/4885TSHR 620/4885HSD17B10 4713/4885 |
| US-20260035361-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | ELAVL1, ELAVL3, HNRNPL | MAPT 624/4885TSHR 1113/4885HSD17B10 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.